Chabiotech KRX:085660KOSDAQ
차바이오텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked12since Sep 11
In Q2 2026, Chabiotech reported revenue of ₩316bn, up 5.9% year on year, and an operating loss of ₩28.2bn. Chabiotech (차바이오텍) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 22 with 1 article.
Filing signals 4 quarters of losses Share pledge Screener
Chabiotech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩316bn | +5.9% | −₩28.2bn margin −8.9% | ₩30.7bn |
| Q1 2026 | ₩330bn | +8.4% | −₩30.7bn margin −9.3% | −₩2.6bn |
| Q4 2025 derived | ₩347bn | +25.6% | −₩7.4bn margin −2.1% | −₩35.3bn |
| Q3 2025 | ₩319bn | +17.2% | −₩8.1bn margin −2.5% | −₩9.2bn |
| Q2 2025 | ₩299bn | +12.9% | −₩20.8bn margin −6.9% | −₩75.2bn |
| Q1 2025 | ₩304bn | +30.9% | −₩12.5bn margin −4.1% | −₩27.0bn |
| Q4 2024 derived | ₩276bn | +14.6% | −₩39.5bn margin −14.3% | −₩29.1bn |
| Q3 2024 | ₩272bn | +14.8% | −₩6.8bn margin −2.5% | ₩20.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Chabiotech top stories 2 weeks, by number of outlets
- 1
Latest Chabiotech news Korean headlines
-
차바이오텍 자회사 마티카 바이오, 美 본드웰과 차세대 단백질 소재 공정 개발
3 more on this story · 3 outlets
- 차바이오텍 자회사 마티카 바이오, 美 본드웰에 단백질 소재 공정개발 서비스파이낸셜뉴스 · Sep 21 09:10
- 차바이오텍 美 자회사 마티카 바이오, 본드웰과 단백질 공정 개발뉴스핌 · Sep 21 09:22
- 차바이오텍 마티카 바이오, 美 본드웰과 단백질 소재 공정 개발 협력뉴스타운 · Sep 21 13:08